JP2022511881A5 - - Google Patents
Info
- Publication number
- JP2022511881A5 JP2022511881A5 JP2021532369A JP2021532369A JP2022511881A5 JP 2022511881 A5 JP2022511881 A5 JP 2022511881A5 JP 2021532369 A JP2021532369 A JP 2021532369A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2022511881 A5 JP2022511881 A5 JP 2022511881A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- hydrophilic
- residue
- position corresponding
- flagellin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776507P | 2018-12-07 | 2018-12-07 | |
| US62/776,507 | 2018-12-07 | ||
| PCT/US2019/064954 WO2020118192A1 (en) | 2018-12-07 | 2019-12-06 | Engineered flagellin-derived compositions and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511881A JP2022511881A (ja) | 2022-02-01 |
| JP2022511881A5 true JP2022511881A5 (cg-RX-API-DMAC7.html) | 2022-12-14 |
Family
ID=70974397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532369A Pending JP2022511881A (ja) | 2018-12-07 | 2019-12-06 | 操作されたフラジェリン由来の組成物と用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220024991A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890769A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022511881A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210111770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113382742A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019392903A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122067A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191610A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283757A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118192A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| CN119522108A (zh) * | 2022-06-01 | 2025-02-25 | 弗莱格生物公司 | Rna佐剂、其方法和用途 |
| KR102896818B1 (ko) * | 2022-10-19 | 2025-12-08 | 전남대학교 산학협력단 | Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용 |
| KR20240081501A (ko) * | 2022-11-14 | 2024-06-10 | 전남대학교산학협력단 | 암의 치료용 면역증강 살모넬라 균주 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121734B1 (en) * | 2007-02-09 | 2013-05-08 | Industry Foundation of Chonam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
| US9376495B2 (en) * | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| CA2903252C (en) * | 2013-03-14 | 2023-01-17 | Research Corporation Technologies, Inc. | Ribotoxin molecules derived from sarcin and other related fungal ribotoxins |
| EP3174893B1 (en) * | 2014-07-30 | 2020-05-06 | Genome Protection, Inc. | Flagellin compositions and uses |
-
2019
- 2019-12-06 EA EA202191610A patent/EA202191610A1/ru unknown
- 2019-12-06 EP EP19892798.0A patent/EP3890769A4/en not_active Withdrawn
- 2019-12-06 CN CN201980090594.0A patent/CN113382742A/zh active Pending
- 2019-12-06 US US17/299,373 patent/US20220024991A1/en not_active Abandoned
- 2019-12-06 CA CA3122067A patent/CA3122067A1/en active Pending
- 2019-12-06 WO PCT/US2019/064954 patent/WO2020118192A1/en not_active Ceased
- 2019-12-06 JP JP2021532369A patent/JP2022511881A/ja active Pending
- 2019-12-06 AU AU2019392903A patent/AU2019392903A1/en not_active Abandoned
- 2019-12-06 KR KR1020217021065A patent/KR20210111770A/ko not_active Ceased
-
2021
- 2021-06-06 IL IL283757A patent/IL283757A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2902150T3 (es) | Agentes aglutinantes de TIGIT y usos de los mismos | |
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| JP2020517700A (ja) | Stingアゴニストを含む抗体コンジュゲート | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| WO2013036574A4 (en) | Modified forms of pseudomonas exotoxin a | |
| AU2013355379A1 (en) | Immunotherapy with binding agents | |
| CN104066748A (zh) | 抗c-met抗体的纯化 | |
| JP7657794B2 (ja) | 免疫療法のための組成物及び方法 | |
| AU2023294103A1 (en) | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof | |
| WO2017147368A1 (en) | Redirecting immune responses | |
| Saini et al. | Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment | |
| JP2021512637A5 (cg-RX-API-DMAC7.html) | ||
| JP2023536655A5 (cg-RX-API-DMAC7.html) | ||
| FI3684813T3 (fi) | Agonistisia CD40-vasta-aineita | |
| TW202237190A (zh) | 抗cea免疫結合物及其用途 | |
| EP3986462A2 (en) | Anti-tim-3 antibodies | |
| CN120018857A (zh) | Gprc5d tcb与imid的组合疗法 | |
| WO2023196876A1 (en) | Il-7ralpha-gamma ligand immunoglobulin fusion proteins | |
| CA3075717A1 (en) | Combination treatment for cancer | |
| CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| IL298883A (en) | Transforming growth factor TGF BETA binding agents and their uses | |
| JP2022547809A5 (cg-RX-API-DMAC7.html) | ||
| WO2019172358A1 (ja) | Hmgn部分ペプチド及びこれを用いたがん療法 | |
| ES2900106T3 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer | |
| EP4090430A1 (en) | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |